

SABINSA NEWS RELEASE

Sabinsa's LactoSpore® Found Safe and Effective for Children

East Windsor, NJ (July 11, 2024) – Sabinsa, a global leader in the nutraceutical and cosmeceutical industries, has had another clinical study on the heat-stable probiotic LactoSpore® [*Weizmannia coagulans* (*Bacillus coagulans*) MTCC 5856] published, adding to the robust body of science on this well-established ingredient.

"*Weizmannia coagulans* MTCC 5856 as adjunct therapy in children's acute diarrhea—a randomized, double-blind, placebo-controlled study" was published in the peer-reviewed journal *Frontiers in Pediatrics* in January 2024. LactoSpore was evaluated in 110 non-hospitalized children in the age group of 1-10 years with acute diarrhea. The children received LactoSpore (400 million spores per day, N = 54) plus oral hydration solution (ORS) and zinc (Zn) or a placebo (N = 56) plus ORS and Zn for 5 days. LactoSpore supplementation along with ORS and Zn resulted in significantly faster recovery from diarrhea in children.

The frequency of diarrhea was lower in children supplemented with the probiotic, and the perceived efficacy score and dehydration status improved significantly. No adverse effects were reported in the children during the study. This randomized controlled study shows that LactoSpore with standard therapy was better than the standard treatment alone in managing acute diarrhea in children.

"All age groups need beneficial bacteria in their gut, and kids especially, so it's important to add to the range of clinical research for common childhood conditions," said Shaheen Majeed, Sabinsa Global CEO & Managing Director. "This clinical proves improvement in efficacy by the inclusion of LactoSpore with the standard treatment of care of oral hydration solution and zinc."

The study may be accessed here: <https://doi.org/10.3389/fped.2023.1338126>

About Sabinsa

Sabinsa, founded by the late Dr. Muhammed Majeed in 1988, is a manufacturer and supplier of standardized herbal extracts, nutraceutical and cosmeceutical ingredients, probiotics, minerals, enzymes, and specialty and fine chemicals. The company markets over 120 standardized botanical extracts and employs more than 1,400 people worldwide in 27 manufacturing, R&D, sales, and distribution facilities. Process development and product innovation form the focus of the ongoing R&D efforts in the company's research facilities, located in India and the U.S. Products, many of which are both Kosher and Halal, are extensively researched, patented, and supported by hundreds of published clinical studies. Sabinsa's botanical cultivation program totals nearly 20,000 acres to ensure sustainable, fair-trade materials are used in these ingredients. For more information, visit sabinsa.com or www.sami-sabinsagroup.com.

Media Contact

Suzanne Shelton - The Shelton Group
Suzanne@SheltonGroupPR.com Cell: +1 847-922-5454